Polypeptide Carrier for HBV Epitope Presentation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current hepatitis B virus (HBV) treatments, particularly for chronic infections, are limited in effectively reducing HBsAg levels and inducing a strong immune response, leading to a high risk of liver diseases and inadequate therapeutic options.
Innovation Solution
Development of a nucleic acid molecule encoding a polypeptide carrier derived from bat HBV core antigens, which forms virus-like particles to present HBV epitopes, enhancing immune recognition and response, and a recombinant protein vaccine that includes these carriers to induce specific immune responses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional HBV treatments (Interferon and nucleoside/nucleotide analogues) are used, then HBV infection can be treated, but HBsAg levels are not effectively reduced and strong immune response is not induced
Solution Approach 1:
The patent uses a polypeptide carrier as an intermediary substance that presents HBV epitopes to the immune system. This carrier acts as a bridge between the HBV antigen and the host immune system, enhancing immune recognition and response while effectively reducing HBsAg levels, which conventional treatments fail to achieve.
Solution Approach 2:
The invention creates a composite structure by fusing the polypeptide carrier with HBV epitopes to form a recombinant protein. This composite molecule combines the immunogenic properties of the carrier with the specific antigenic determinants of HBV, resulting in enhanced immune response and effective clearance of HBsAg.
2Reliability
If existing vaccines are used, then some immune protection is provided, but immune response against HBV is insufficient for chronic infections
Solution Approach 1:
The patent modifies key parameters of the vaccine by changing the carrier protein structure and selecting specific HBV epitopes. These parameter changes in the antigen structure result in enhanced immunogenicity and adaptability, generating a stronger and more effective immune response against chronic HBV infections compared to conventional vaccines.
3Reliability
If nucleic acid molecule encoding polypeptide carrier is developed, then effective HBV treatment strategy is achieved, but device complexity and manufacturing complexity increase
Solution Approach 1:
The patent divides the complex task of HBV treatment into manageable segments: (1) designing the polypeptide carrier structure, (2) selecting and inserting HBV epitopes, (3) constructing the nucleic acid encoding sequence, and (4) producing the recombinant protein. This segmentation of the development process makes the complex nucleic acid molecule construction more systematic and feasible.
Data Source
AI summary
The invention relates to a polypeptide carrier for presenting a target polypeptide, and use thereof. In particular, the invention relates to a nucleic acid molecule, comprising a nucleotide sequence encoding a polypeptide carrier, and being used for insertion of a nucleotide sequence encoding a target polypeptide. In addition, the invention further relates to a recombinant protein comprising the polypeptide carrier and a target polypeptide. Furthermore, the invention further relates to use of the nucleic acid molecule and the recombinant protein. In addition, the invention further relates to a vaccine or a pharmaceutical composition useful for preventing, alleviating or treating HBV infection or a disease associated with HBV infection (e.g., hepatitis B), comprising a recombinant protein comprising the polypeptide carrier of the invention and an epitope from HBV.